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Objectives: To investigate the prevalence of GB virus C (GBV-C)/hepatitis G virus (HGV) RNA and anti-E2 antibodies in 
different risk groups of HIV-infected patients compared to that in healthy blood donors, and to  study the effects of 
possible interactions between HIV and GBV-C/HGV on the carrier state and hepatic changes. 
Methods: Sera from 100 consecutive unselected HIV-infected outpatients and from 100 healthy blood donors were 
screened for GBV-C/HGV viremia and anti-E2 antibodies. Anti-E2 antibodies were detected using an immunoassay 
developed by Boehringer Mannheim according to the manufacturer's instructions. GBV-C/HGV RNA was extracted from 
sera and reverse transcribed. The resulting cDNA was amplified with a PCR developed in the laboratory with primers 
derived from the 5' noncoding region of the viral genome and detected with a specific capture probe. This procedure 
was validated by a French multicenter quality control group. 
Results: Thirty-one of the 100 HIV-infected patients and 8% of the healthy blood donors displayed anti-E2 antibodies. 
Four HIV-infected patients and one healthy blood donor were found to be GBV-C/HGV viremic. When analyzed by risk 
factor for the acquisition of HIV, no differences in the prevalence of anti-E2 antibodies were found between intravenous 
drug users and homosexual and heterosexual patients. 
Conclusions: We found a high prevalence of GBV-C/HGV infection in the HIV-infected population, irrespective of the 
risk group factor for HIV infection, suggesting that the sexual route is as effective as the parenteral route for the 
acquisition of GBV-C/HGV. No biological alteration could be attributed to  GBV-C/HGV, even in the viremic patients. HIV- 
infected patients were able to  clear GBV-C/HGV viremia and to mount a humoral immune response. 
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INTRODUCTION 
GB virus C (GBV-C) [l] and hepatitis G virus (HGV) 
[2] have been shown to be the same virus, and belong 
to the Flaviviridae family. It  is a positive single-strand 
Corresponding author and reprint requests: 
J. Durant, Department of Infectious and Tropical Diseases, 
CHU Nice, HBpital de I'Archet, Rte de St Antoine de 
Ginestiere, BP 3079F, 06202 Nice Cedex 3, France 
Tel: t 3 3  4 92 03 54 73 Fax: +33 4 92 03 54 69 
E-mail: 
Accepted 20 May 1998 
KNA virus distantly related to HCV. GBV-C/HGV 
infection was initially diagnosed by KT-PCK amplifi- 
cation of the genome in the blood. Its presence in 
the blood of patients already infected with HBV, HCV 
or HIV and also normal blood donors has been 
demonstrated worldwide. The prevalence of GBV- 
C/HGV viremia varies from 11% aniong prostitutes in 
Taiwan [3] to 33% among intravenous drug users 
(IVDUs) in Germany 141. It is also frequent in normal 
blood donors, with a prevalence of viremia of 1-4% 
[4,5], and as high as 7.4%) in healthy Vietnamese blood 
donors [6]. 
In the meantime, a humoral immune response to 
the envelope protein E2 of GBV-C/HGV was shown 
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to be associated with the loss of detectable viremia and 
could serve as a useful marker for monitoring recovery 
from GBV-C/HGV infection [7]. Effectively, the 
prevalence of anti-GBV-C/HGV antibodies increases, 
while the prevalence of GBV-C/HGV R N A  signi- 
ficantly decreases among IVDUs who inject for a 
longer period of time [7]. The presence of anti-GBV- 
C/HGV antibodies and the presence of GBV-C/HGV 
RNA are almost mutually exclusive. In one series, only 
4% of the IVDUs were positive for both markers at the 
same time [7]. An immunoassay was later developed to 
detect anti-E2 antibodies. The prevalence of anti-E2 
antibodies was shown to vary between 9% in blood 
donors and 41% in IVDUs [7]. Parenteral [ 8 ] ,  sexual [3] 
and vertical [9] transmission of GBV-C/HGV have 
been observed. 
Although the virus was first described during 
the searching for a non-A-E hepatotropic virus, its 
pathogenic role is still unclear. Acutely or chronically 
infected patients show few or no biological abnor- 
malities, and the role of GBV-C/HGV in acute or 
chronic hepatitis, fulminant hepatitis or the hepatitis- 
aplastic syndrome is debated [8,10-121. Persistent 
viremia of unknown significance can last for several 
years [&lo]. 
Persistence of viremia, development of liver disease 
and seroprevalence of anti-E2 antibodies have not been 
extensively studied in a severely immunocompromised 
population of HIV-infected patients. In this study we 
investigated the prevalence of GBV-C/HGV R N A  
and anti-E2 antibodies in different risk groups of 
HIV-infected patients compared with that in healthy 
blood donors. We also studied the possible interactions 
between HIV and GBV-C/HGV on the carrier state 
and hepatic changes. 
PATIENTS 
Between 3 and 27 February 1997, one hundred HIV- 
infected patients, consecutively attending for outpatient 
consultation in Nice, southeast France, were tested 
for GBV-C viremia and anti-E2 antibodies (Table 1). 
There were 82 males and 18 females with a mean age 
of 38 years; 29 were heterosexuals, 36 homosexuals, 
and 35 IVDUs. Thirty-seven were classified as C D C  
stage A, 40 CDC stage B, and 23 CDC stage C. 
Markers for HCV and HBV infections were 41% 
positive for HCV antibodies, 11% positive for HBs 
antigen, 54% positive for anti-HBc antibodies, and 11% 
positive for HBs antibodies. Serum aminotransferase 
levels and antiretroviral treatment were also recorded. 
One hundred sera from anonymous healthy blood 
donors were also screened for GBV-C/HGV viremia 
and anti-E2 antibodies. 
Table 1 Clinical and virologic characteristics of the 100 
HIV-infected patients 
Data Patients n=100 
Male/Female 
Age (years) 
Viral load (log) 
CD4/mm3 
Risk factor 
Heterosexual 
Homosexual 
Intravenous drug user 
Stage A 
Stage B 
Stage C 
HBsAg 
Anti HBs 
Anti HBc 
Anti HCV 
CDC 
82/18” 
38?7” 
266f 71a 
3 . 5 f l . l a  
29 (29%) 
36 (36%) 
35 (35%) 
37 (37%) 
40 (40%) 
23 (23%) 
3 (2.1%) 
11 (11%) 
54 (54%) 
41 (41%) 
“Mean? SD. 
METHODS 
GBV-C/HGV anti-E2 ELISA 
Antibodies to the envelope protein E2 were detected 
by a two-step sandwich ELISA using a streptavidin 
link (Microplate anti-HGenv, Boehringer Mannheim, 
Penzberg, Germany). The positive results were vali- 
dated with a confirmatory test, omitting E2 antigen in 
the incubation mixture. 
GBV-C/HGV RNA PCR assays 
Aliquots of sera were stored at  -80°C until thawed for 
R N A  extraction. R N A  was extracted from 50 pL 
serum by the acid guanidinium thiocyanate/phenol/ 
chloroform method [13]. The reagent was Trizol 
LS (Life Technologies, Gaithersburg, MD, USA). 
Complementary DNA synthesis was carried out with 
random hexamers (Boehringer Mannheim, Germany). 
The resulting cDNA was amplified by RT-PCR, 
developed in our laboratory, using primers derived 
from the 5’ noncoding region of the viral genome 
and detected with a corresponding capture probe. The 
primers were 5’-CCGGCCAAAAGGTGGTGGA- 
TGG-3’ (sense: nucleotides 99-120) and 5’- 
GACATTGAAGGGCGACGTGGACC-3’ (antisense: 
nucleotides 353-331) generating a 255-bp fragment. 
The nucleotide sequence was based on the prototype 
HGV genome [2]. P C R  was performed on a Perkin- 
Elmer 9600 thermocycler with 45 cycles at 94OC 
for 15 s, 55OC for 30 s, and 72OC for 30 s, followed by 
a single extension step at 72°C for 3 min. Recom- 
mended precautions to avoid possible cross-contamina- 
tion were taken [14]. The specificity of the P C R  
products was assessed by hybridization with a specific 
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biotinylated capture probe (Boehringer Mannheim, 
Germany): 5’-GGTAGCCACTATAGGTGGG-3’ 
(nucleotides 161-179). This procedure was validated, 
with 100% sensitivity and 100% specificity, by a French 
multicenter quality control study which included 22 
specialized laboratories (unpublished data). 
Serum HBV markers were detected using immuno- 
assays from Abbott Laboratories (Chicago, IL, USA), 
and antibodies to HCV were tested with two third- 
generation immunoassays (Ortho HCV 3.0, and Abbott 
HCV 3.0). 
RESULTS 
Anti-E2 detection 
Thirty-one of the 100 HIV-infected patients and eight 
of the healthy blood donors displayed anti-E2 anti- 
bodies. Four HIV-infected patients and one healthy 
blood donor were found to be GBV-C/HGV viremic 
(Figure 1). When analyzed by risk factor for the acqui- 
sition of HIV, no difference in the prevalence of anti- 
E2 antibodies was found between IVDU, homosexual 
and heterosexual patients (Table 2). HCV and HBV 
co-infections were more prevalent in IVDUs. Hetero- 
sexuals showed a prevalence of infection with GBV- 
4Q  
35 1 31 I 
” 
~ ~~~ ~ 
Healthy blood donors HIV positive 
C/HGV similar to that with HBV. Co-infection with 
other hepatotropic viruses was frequent: of the 31 
patients who were anti-E2 positive, 11 were co- 
infected with HCV and HBV, three with HBV alone, 
and six with HCV alone, while 11 acquired only GBV- 
C/HGV. There were no differences in CD4 levels or 
HIV plasma viral load between the anti-E2-positive and 
the antiGE2-negative patients (Table 3). 
The prevalence of viremia was low in our HIV- 
infected patients and similar to that in the general 
population. Of  the four viremic patients (Table 4), two 
homosexuals were diagnosed as HIV-infected more 
than 10 years ago, while the other two (heterosexual) 
patients had been diagnosed as HIV+ for less than 1 
year. They all had normal aminotransferase levels. 
Three were receiving anti-HIV therapy comprising 
zidovudine and/or zalcitabine, and/or didanosine; the 
fourth remained untreated. None of them received 
lamivudine at  the time they were viremic, while 26 
of 31 of the anti-E2-seropositive, GBV-C/HGV 
RNA-negative patients received antiretroviral agents, 
including lamivudine. Three of the four viremic 
Table 2 Prevalence of anti-E2 and HGV RNA in 
HIV-infected pattients according to risk factors 
LY Anti-E2 (“Yo) H G V  R N A  (%) 
H I V  patients 100 31 4 
IVDU 33 10 (28.6) 0 
Homosexual 36 13 (36.1) 2 (5.5) 
Heterosexual 29 8 (27.6) 2 (6.9) 
Table 3 Clinical and virologic characteristics according to 
the presence of HGV 
HGV RNA’ HGV RNA- AntiGE2’ ,4nti-E2- 
tl =4 r r = %  rr=31 11 =6S 
AST 32.5+8.7“ 48 4247.9 46.3i37.2 49.4k52.4 
ALT 25-tl1.1 56.3271.7 56.2i65.3 56.5275.1 
Viral load (log) 4.1k2.5 3.5-ta.l 3.4-tO.9 3.5-tl.l 
CD4/nini’ 121 + I n 9  272k170 249 k l j9  283+ 175 
‘Meank’jD 
AST. as~ar ta te  aminotrancferase (nornial ranee 10-17 u/L)  Figure 1 Prevalence of anti-E2 and HGV-RNA in HIV- ” 
infected patients and healthy blood donors. ALT, alanine aminotransferase (normal range 10-41 u /L) .  
Table 4 Clinical and biological data of the four HGV RNA-positive patients 
Normal L a m -  
l’mcnts Scx Agc Contamination transanunasc HBsAg anti-HBc anti-HBs anti-HCV Anti-Ea vudinr 
No  1 M 42 Homosexual Yet + + 
7 - - N 0 F 25 Hctrrosrxual Ye5 + + 
NO i M 38 Heterosexual Yrc 
No + 4 M 32 Homosexual Yrc 
- - - 
- 
- - - - - 
- - - - 
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patients were subsequently given lamivudine as part of 
their anti-HIV therapy. After 6 months, viremia was 
still present in two. The viremic patient not given 
lamivudine became negative. 
DISCUSSION 
This study showed a high prevalence of GBV-C/HGV 
infection in the HIV-infected population that appeared 
to be independent of the risk factors for the acquisition 
of HIV. Thirty-one of the 100 (31%) HIV-infected 
patients displayed anti-E2 antibodies. This prevalence 
was more than three times higher than that of the blood 
donor population, in which only eight of 100 (8%) 
were found to be anti-E2 positive. Serologic evidence 
of past infection with GBV-C/HGV was equally 
distributed among the different risk groups for the 
acquisition of HIV, suggesting that GBV-C/HGV 
can be acquired through the sexual route as well as 
parenterally. IVDUs are known to engage in unsafe 
sexual behavior, and some of them could have acquired 
GBV-C/HGV by the sexual route instead of the 
intravenous route. However, as the prevalence of anti- 
GBV-C/HGV antibodies was s i d a r  in the three risk 
groups, our results suggest that unsafe sexual behavior 
may be as risky for the acquisition of GBV-C/HGV as 
sharing needles for drug use, associated or not with 
practising unsafe sex. 
Among the blood donors, the prevalence of 8% 
anti-E2-positive and 1% viremic patients was com- 
parable to that described elsewhere [2,7,8]. 
Our patients had a lower prevalence of viremia 
than that described for other similar risk groups [4]. 
This could be due to the acquisition of GBV-C/HGV 
much earlier, with the development of an antibody 
response and disappearance of viremia. GBV-C/HGV 
RNA positivity and anti-E2 positivity rates were found 
to be 53% and 35%, respectively, in IVDUs with a 
duration of drug use of less than 5 years, compared to 
30% and 48%, respectively, in IVDUs with a duration 
of drug use of more than 10 years [7].  In our study, the 
presence of anti-E2 and GBV-C/HGV R N A  appeared 
to be mutually exclusive. This agrees with the series 
showing only 4% of IVDUs positive for both markers 
at the same time [7].  Although we do not know if they 
acquired their infection while already infected with 
HIV, the severe immunosuppression they suffer does 
not seem to impede the natural recovery from GBV- 
C/HGV infection, in agreement with another series 
of HIV-infected patients [15]. The alanine amino- 
transferase levels were associated with a co-infection 
with HCV or HBV and were independent of 
GBV-C/HGV infection. This was found not only 
in the GBV-C/HGV RNA-negative, anti-E2-positive 
patients, but also in the viremic patients. The possible 
role of antiretroviral therapy, in particular lamivudine, 
on GBV-C/HGV viremia needs further study. 
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